| Autor: |
Ashton, Juliet H., Golino, Paolo, McNatt, Janice M., Buja, L.M., Willerson, James T. |
| Zdroj: |
Journal of the American College of Cardiology; March 1989, Vol. 13 Issue: 3 p755-763, 9p |
| Abstrakt: |
The object of this study was to test the hypothesis that administration of both serotonin S2and thromboxane A2-prostaglandin H2(PGH2) receptor antagonists provides significant protection against epinephrine-induced cyclic coronary artery flow variations in open chest, anesthetized dogs with severe proximal coronary artery stenosis and endothelial injury. Three groups of dogs were studied. In Group 1(n = 7) and Group 2 (n = 6), cyclic coronary flow variations were initiated after placement of a concentric constrictor around the left anterior descending coronary artery and were abolished by administration of either a thromboxane A2-prostaglandin H2receptor antagonist, SQ29,548 (SQ) (Group 1), or a serotonin S2receptor antagonist, LY53,857 (LY) (Group 2). Cyclic flow variations were restored with an epinephrine infusion and the second antagonist (LY for Group 1; SQ for Group 2) was administered to abolish epinephrine-induced cyclic flow variations. The rate of epinephrine infusion was increased until cyclic coronary flow variations returned (n = 8) or significant hemodynamic changes occurred. Plasma epinephrine concentrations were determined during a control period of cyclic coronary flow variations, after epinephrine restored cyclic flow variations in the presence of either SQ or LY, and again after epinephrine restored cyclic flow variations in the presence of both SQ and LY. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
